The enzyme coenzyme A-independent transacylase (CoA-IT) has been demonstrated to be the key mediator of arachidonate remodeling, a process that moves arachidonate into 1-ethercontaining phospholipids. Blockade of CoA-IT by reversible inhibitors has been shown to block the release of arachidonate in stimulated neutrophils and inhibit the production of eicosanoids and platelet-activating factor. We describe novel inhibitors of CoA-IT activity that contain a ␤-lactam nucleus. ␤-Lactams were investigated as potential mechanism-based inhibitors of CoA-IT on the basis of the expected formation of an acyl-enzyme intermediate complex. Two ␤-lactams, SB 212047 and SB 216754, were shown to be specific, timedependent inhibitors of CoA-IT activity (IC 50 ϭ 6 and 20 M, respectively, with a 10-min pretreatment time). Extensive washing and dilution could not remove the inhibition, suggesting it was irreversible. In stimulated human monocytes, SB 216754 decreased the production of eicosanoids in a time-dependent manner. In an in vivo model of phorbol ester-induced ear inflammation, SB 216754 was able to inhibit indices of both edema and cell infiltration. Taken together, the results support two hypotheses: 1) CoA-IT activity is important for the production of inflammatory lipid mediators in stimulated cells and in vivo and 2) the mechanism by which CoA-IT acts to transfer arachidonate is through an acyl-enzyme intermediate.
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CoA-IT is an enzyme responsible for the remodeling of arachidonate between different phospholipids (Snyder et al., 1992; . Specifically, CoA-IT seems to selectively remodel arachidonate and other long-chained, unsaturated fatty acids (Chilton et al., 1983; Kramer and Deykin, 1983; Sugiura et al., 1987; Winkler et al., 1991) . Additional studies showed that it is responsible for the remodeling of arachidonate from 1-acyl-containing phospholipids into 1-alkyl-and 1-alkenyl-containing phospholipids (Chilton and Murphy, 1986; Sugiura et al., 1987) . To explore the role of CoA-IT in inflammatory cells, we reported previously the characterization of tool compounds that block CoA-IT activity and arachidonate remodeling . Using these tools, we demonstrated that this CoA-ITmediated movement of arachidonate is important for several functions of stimulated inflammatory cells, including the production of PAF, release of free AA, and production of prostanoids .
Because of the importance of CoA-IT to inflammatory cell function, it is meaningful to gain insight to its mechanism of action. We hypothesized previously that the enzyme CoA-IT is part of a family of transacylases, typified by lecithin cholesterol acyl-transferase . This hypothesis details a catalytic mechanism in which an active site nucleophile in CoA-IT attacks the acyl carbonyl of the sn-2 arachidonate of phospholipids, forming a covalent interaction between arachidonate and CoA-IT and liberating lyso phospholipid. The covalently attached arachidonate then can be donated to a suitable lyso phospholipid acceptor. Based on this mechanism, the same CoA-IT nucleophile could attack the ketone within a ␤-lactam ring, opening the ring and forming a covalent interaction between CoA-IT and the ␤-lactam-containing compound. Further reaction by decomposition of ␤-lactams, such as penicillins and cephalosporins, resulting in stable enzyme/product coupling, is well docu-were separated by TLC in chloroform/methanol/acetic acid/water (50:25:8:4, v/v/v/v; System I, Analtech, Newark, DE) and visualized by radioscanning (Bioscan, Washington, D.C.). The product, 1-[ 3 H]alkyl-2-acyl-GPC, was scraped and quantified by liquid scintillation spectroscopy. With this TLC system, the R F values for synthetic standards of 1-alkyl-2-lyso-GPC and 1-alkyl-2-acyl-GPC were ϳ0.24 and ϳ0.64, respectively. Enzyme assays. PLA 2 activities were determined using [ 3 H]arachidonate-labeled Escherichia coli membranes by measuring the liberation of free [
3 H]AA (Marshall and McCarte-Roshak, 1992) . Human type II, 14-kDa PLA 2 was purified from a clone expressed in Chinese hamster ovary cells (Stadel et al., 1992) . Cytosolic 85-kDa PLA 2 (Kramer et al., 1991) was obtained from a clone expressed in baculovirus-infected insect cells (Amegazie et al., 1993) . 5LO activity was measured by monitoring O 2 consumption in a reaction mixture of 10 M AA, 5 M sonicated dioleoyl phosphatidylcholine, 150 mM NaCl, 5% ethylene glycol, and 0.2 mM CaCl 2 . 5LO activity was obtained from the cytosolic fraction (100,000 ϫ g, 60 min) of RBL-1 cells. Cyclooxygenase activity was measured using the enzyme from ram seminal vesicles, incubated with 50 M AA (Rabinovici et al., 1993) . The reaction was terminated by the addition of 10% trichloroacetic acid, and products were quantified by absorbance at 532 nm. CoA-dependent acylation activity was determined using U937 microsomes that were diluted in Tris buffer (100 mM, pH 7.4) and incubated with 12-15 M acyl-CoA and 0.015 Ci 1-[ 14 C]-acyl-2-lyso-GPC with 1 M cold 1-acyl-2-lyso-GPC. After 10 min at 37°, the samples were extracted and developed on TLC plates (System I), and the amount of 1,2-diacyl-GPC product was determined. PLA 2 activities were determined using E. coli membranes by measuring the liberation of free [ 3 H]AA (Marshall and McCarte-Roshak, 1992) . Lyso PAF:acetyltransferase activity was determined as described previously , by measuring the production of [ PAF production by intact neutrophils. The incorporation of [ 3 H]acetate into 1-radyl-2-lyso-GPC during cell activation was used to quantify PAF biosynthesis (Mueller et al., 1983; . Cell suspensions (10 ϫ 10 6 cells/ml) in PBS containing 1 mM Ca 2ϩ and 1.1 mM Mg 2ϩ were incubated at 37°in a volume of 950 l and exposed to drugs or vehicle for the indicated times. Then, 50 l of a solution containing [ 3 H]acetic acid (30 Ci) with A23187 (1 or 2 M final) in PBS with Ca 2ϩ , Mg 2ϩ , and 1 mg/ml BSA was added to the cell suspensions. After 10 min at 37°, the reactions were terminated by the addition of 1 volume of chloroform/methanol (1:2, v/v), and the lipids were extracted (Winkler et al., 1991) . After extraction of total lipids, individual phospholipids were separated by TLC on silica gel G plates developed in chloroform/methanol/glacial acetic acid/water (50:25:8:4, v/v/v/v) and localized by radioscanning (Bioscan). The area corresponding to PAF was then scraped and quantified by liquid scintillation counting. In human neutrophils, ϳ90% of the 1-radyl-2-[ 3 H]acetyl-GPC produced under these conditions is 1-alkyl-2-acetyl-GPC (Triggiani et al., 1991) .
Eicosanoid assays. After stimulation of inflammatory cells, the cells were pelleted by brief centrifugation, and the supernatant fluids were collected. The mole quantities of three different eicosanoids (LTB 4 , LTC 4 , PGE 2 ) in the supernatants were determined with enzyme immunoassay kits (Cayman, Ann Arbor, MI) used according to the manufacturer's directions.
Mouse ear inflammation. The inner and outer surfaces of the left ears of BALB/c male mice (six per group) were treated with vehicle or phorbol ester (4 g/ear, phorbol-12-myristate-13-acetate; Sigma). SB 216754 was applied topically immediately after the challenge, and its effects were compared with those of the dimethylsulfoxide vehicle. After 4 hr, ear thickness was measured as an index of the edematous response, and the myeloperoxidase activity of the inflamed ears was determined on tissue homogenates as an index of cellular infiltration .
␤-Lactam Coenzyme A-Independent Transacylase Inhibitors
Protein analysis. Protein concentrations were determined according to the method of Bradford (1976) 
Results
Selectivity profiles of SB 212047 and SB 216754. The ability of SB 212047 and SB 216754 to inhibit CoA-IT activity in microsomes of U937 cells in a concentration-dependent manner was determined, using a 10-min preincubation time, as shown in Fig. 1 . As initial assessment of time-dependent inhibition, the compounds were incubated with U937 microsomes for 80 min before the activity measurement. As can be observed in Fig. 1 , a longer preincubation time decreases the apparent IC 50 value.
As a test for selectivity, the ability was assessed of these compounds to inhibit other enzymes involved in lipid metabolism. As shown in Table 1 , both compounds had minimal effects on several other enzymes, suggesting that their inhibition of CoA-IT activity was reasonably selective. In addition, SB 212047 was found to inhibit the activity of 85-kDa PLA 2 , and SB 216754 could inhibit the activities of 5LO and acetyltransferase. However, these effects were observed at higher concentrations than those needed to inhibit CoA-IT and, importantly, were not time dependent (data not shown). These results suggest that only CoA-IT was inhibited by these compounds in a mechanism-based, time-dependent manner.
Kinetics of CoA-IT inhibition. Several series of experiments were performed to characterize further the mechanism by which these compounds inhibited CoA-IT activity; these included studies on the kinetics of CoA-IT inhibition, ability of substrate to protect against inhibition, and reversibility of the inhibition.
Microsomes from U937 cells containing CoA-IT activity were treated with different concentrations of ␤-lactam SB 212047, and the loss of activity was measured over time ( Fig.  2A) . The data show that the inhibition of CoA-IT was progressive over time and essentially complete by 80 min. In a similar fashion, SB 216754 and two compounds of related structures (SB 216610 and SB 219204; 10-min IC 50 ϭ 20 and 75 M, respectively) caused inhibition of CoA-IT activity that was dependent on pretreatment time (Fig. 2B) .
To test for the ability of substrate to protect against inhibition of CoA-IT by ␤-lactam inhibitors, experiments were performed in which 1 M lyso-PAF substrate was added at the same time as the inhibitor and CoA-IT activity was measured in a 10-min assay. Under such experimental conditions, both SB 212047 (20 M) and SB 216754 (20 M) do not inhibit CoA-IT activity (data not shown), suggesting substrate protection is effective.
Experiments were performed to attempt to recover CoA-IT activity after inhibition by ␤-lactams. Microsomes containing CoA-IT activity were incubated with SB 212047 (40 M) for 80 min, such that Ͼ90% of the activity was inhibited. These microsomes then were washed with PBS and centrifuged (100,000 ϫ g, 60 min) three separate times. After each centrifugation, CoA-IT activity was measured and still found to be inhibited by Ͼ90% (data not shown). In addition, microsomes of U937 cells containing CoA-IT activity were incubated with ␤-lactam SB 216754 for 0 or 30 min and then diluted 20-fold directly into assay conditions; CoA-IT activity was measured. As shown in Fig. 3 , minimal inhibition of CoA-IT activity is observed at the final concentration of inhibitor if the microsomes are diluted immediately after the addition of the compound. In contrast, when the compound was incubated with the microsomes for 30 min before dilution, inhibition of activity is observed, indicating that inhibition is a time-dependent process. Similar results were obtained with SB 212047 (data not shown).
Finally, the ability of CoA-IT activity to recover from ␤-lactam inhibition was measured over longer time periods. U937 microsomes were treated with SB 216754 (300 M) and diluted to decrease the effective concentration of the compound to 15 M, and then CoA-IT activity was measured over a 6-hr period. The results (Fig. 4) show no indication of recovery of CoA-IT activity over the 6-hr period.
Influence of SB 212047 and SB 216754 on lipid mediator production. We have shown previously that inhibition of CoA-IT activity in inflammatory cells, using competitive inhibitors, resulted in decreases in the ability of those cells to produce inflammatory mediators . We extended this study to examine the cellular pharmacology of the irreversible ␤-lactam compounds. Treatment of human neutrophils with up to 30 M SB 212047 had no effect on the ability of those cells to produce PAF (20% inhibition compared with A23187 control response; three experiments; p ϭ N.S.). One possible explanation of this lack of cellular effect of this compound is a lack of cellular stability. This hypothesis was tested in vitro by the addition of glutathione to mimic the reducing environment within the cell. Glutathione (100 M) reduced the ability of 30 M SB 212047 to inhibit CoA-IT in microsomes [CoA-IT activity (mean Ϯ standard error) for control, 16,287 Ϯ 477 dpm; glutathione, 16,153 Ϯ 418 dpm (99%); SB 212047, 677 Ϯ 205 dpm (4%); and glutathione plus SB 212047, 15,466 Ϯ 330 dpm (95%)]. This suggests a possible mechanism by which the compound may lack stability within the cell and thus have no inhibitory effect on PAF production
In contrast to SB 212047, the ability of SB 216754 to inhibit CoA-IT activity was not affected by glutathione treatment, and thus this compound could be predicted to have the potential to block the production of lipid mediators in human inflammatory cells. Fig. 5 shows that SB 216754 inhibited PAF production in neutrophils (IC 50 ϭ 5 M). SB 216754 also was able to affect the production of both LTC 4 and PGE 2 in human monocytes, as shown in Fig. 6 . Importantly, the effectiveness of SB 216754 for inhibition of the production of these mediators increased with longer pretreatment times (Figs. 5 and 6) .
Effect of inhibition of CoA-IT on inflammation in vivo. The profile of SB 216754 as an inhibitor of CoA-IT is that of a compound causing a broad reduction in the production of a variety of lipid mediators in isolated inflammatory cells. To test whether this profile would translate into antiinflammatory effects in an in vivo setting, we selected phorbol ester-induced inflammation in the mouse ear, a model of inflammation in which a variety of lipid mediators are produced. In this model, inflammation has been attributed to the production of a variety of lipid inflammatory mediators, including LTs, PGs, and PAF Merlos et al., 1991) . We extensively characterized this model, and we and others have shown previously that inflammation can be blocked by inhibitors of PLA 2 and by dexamethasone (Tramposch et al., 1992; Miyake et al., 1993; Marshall et al., 1994 Marshall et al., , 1995 . In addition, we have shown that topical application of the CoA-IT inhibitor SK&F 98625 or SK&F 45905 to the ear prevented both edema and inflammatory cell influx induced by the inflammatory stimulus . In a similar fashion, the current study shows that SB 216754 inhibited both indices of the inflammatory response in the mouse ear (Table 2) .
Experiments were performed in which animals were treated with SB 216754 and then tissue prepared to examine CoA-IT activity. Because SB 216754 is an irreversible inhibitor of CoA-IT activity, inhibition of activity that occurred in vivo would be expected to be detected in a subsequent ex vivo assay. In such an experiment, mice were treated with phorbol ester or vehicle and then with SB 216754 (0.75 mg/ear); ear edema and CoA-IT activity were measured after 4 hr. There was a good correspondence between inhibition of inflammatory edema (Ϫ73%) and inhibition of CoA-IT activity (Ϫ62%) (control, 34 Ϯ 2; phorbol ester, 42 Ϯ 6; phorbol ester plus SB 216754, 37 Ϯ 1 pmol/min/mg). An additional experiment was performed to examine whether this correspondence continued during a chronic inflammatory response. Mice were treated with phorbol ester or vehicle and then with SB 216754 (0.75 mg/ear twice daily for 3 days), after which the tissue content of CoA-IT activity was determined. Phorbol ester treatment increased CoA-IT activity, whereas SB 216754 inhibited this increase by 70% (control, 38 Ϯ 13; phorbol ester, 58 Ϯ 6; phorbol ester plus SB 216754, 45 Ϯ 8 pmol/min/mg). In the same mice, SB 216754 demonstrated statistically significant decreases in both edema (Ϫ26%) and myeloperoxidase (Ϫ47%). These results strengthen the hypothesis that the anti-inflammatory effects observed with SB 216754 could be ascribed to inhibition of CoA-IT activity.
Discussion
Although much is known about the activity of CoA-IT, key information on its structure and mechanism of action remains to be uncovered. As a working model, we proposed that the mechanism of action of CoA-IT may be similar to that determined for lecithin cholesterol acyl-transferase (Jauhiainen and Dolphin, 1986; ). This proposal is based on inhibitor studies showing that the activity of CoA-IT is inhibited by the serine esterase inhibitor N-tosyl-L-phenylalanine chloromethyl ketone, the histidine modifier diethyl pyrocarbonate, and agents that modify cysteine residues, such as N-ethylmaleimide (Kramer and Deykin, 1983; Winkler et al., 1991) . However, this proposed mechanism of action of CoA-IT remains difficult to prove in the absence of purified enzyme with sequence details. One attempt to further our understanding of this enzyme involves the investigation of ␤-lactams as mechanism-based inhibitors.
A large number of ␤-lactam-containing compounds were screened for inhibition of CoA-IT, but only a few were found to be inhibitors. The experiments described herein demonstrate that specific ␤-lactam compounds can inhibit CoA-IT activity with many characteristics used to define mechanismbased inhibition: concentration dependence, time dependence, irreversibility, selectivity, and substrate protection. Furthermore, SB 216754 was shown to block the production of inflammatory lipid mediators in human neutrophils and monocytes and to inhibit indices of the inflammatory response in vivo. Two major conclusions can be drawn from these results. The first is that these studies provide further support for the critical role that CoA-IT plays in the inflammatory response. The second is that these results show that specific ␤-lactams can interact with CoA-IT to irreversibly inactivate the enzyme. Concerning the mechanism by which ␤-lactams inhibit CoA-IT, we hypothesize the first step to be the opening of the ␤-lactam by an active site nucleophile, normally involved in the hydrolysis of the sn-2 fatty ester of the donor substrate. The resulting acyl-enzyme intermediate then could be a stable, in effect irreversible, complex, or it may undergo rearrangement and further reactions, such as that classically proposed for clavulanic acid (Brenner and Knowles, 1981) . The irreversible nature of the complex, if an acyl-intermediate, suggests that water is excluded rigorously from the active site. This would not be surprising for a membranebound, lipid-metabolizing enzyme. 
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Concerning the role of CoA-IT in inflammation, previous studies have shown a link between CoA-IT activity and PAF biosynthesis, both in broken-cell preparations (Uemura et al., 1991; Venable et al., 1991; Winkler et al., 1992) and in whole cells (Sugiura et al., 1990) . Moreover, CoA-IT activity seems to be linked to the transfer, and the rate of transfer, of arachidonate between specific subcellular pools (Fonteh and Chilton, 1992; Winkler et al., 1994) . Two previously described inhibitors of CoA-IT, SK&F 98625 and SK&F 45905, were able to inhibit arachidonate movement as well as PAF, LT, and PG production . These effects in isolated cell systems translated into anti-inflammatory effects in a specific in vivo setting of inflammation. The current results with the ␤-lactam CoA-IT inhibitor SB 216754 support these previous findings. The data showing SB 216754 reduced lipid mediator production in a time-dependent fashion is particularly strong support for the role of CoA-IT in this response.
As with any tool compound, selectivity always is a concern. SB 216754 was found to inhibit 5LO and acetyltransferase at higher concentrations but not in a time-dependent manner. In addition, the effects of this compound on other enzymes, such as those involved in de novo phospholipid biosynthesis, are unknown. Thus, cellular and in vivo results should be viewed with proper caution. It is encouraging, however, that three structurally diverse compounds that are inhibitors of CoA-IT (SB 216754, SK&F 45905, and SK&F 98625) have the same pharmacological effects in cells and in vivo.
In summary, specific ␤-lactam compounds can inhibit CoA-IT activity in a concentration-and time-dependent manner. Treatment of inflammatory cells with a ␤-lactam CoA-IT inhibitor resulted in a time-dependent reduction in the ability of those cells to produce inflammatory mediators. The characteristics of inhibition of CoA-IT by the ␤-lactam compounds support a mechanism of action involving a covalent interaction between the inhibitors and CoA-IT enzyme. Balb/c mice were given phorbol-12-myristate-13-acetate followed by test compound. The edematous response was measured using a thickness gauge 4 hrs after phorbol-12-myristate-13-acetate application. The animals were killed, the inflamed ears were harvested, and myeloperoxidase was extracted and assayed spectrophotometrically as described in Experimental Procedures. Both compounds produced effects significantly different from vehicle treatment.
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